OSLER was a randomized trial comparing long-term evolocumab plus standard therapy vs. standard therapy alone.
MAIN RESULTS:
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
N Engl J Med. 2015 Apr 16;372(16):1500-9.
PRESENTATIONS
OSLER Outcomes (Sabatine, ACC 2015)
